newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Data presented at the Society for Immunotherapy of Cancer Spring Scientific 2025 Cell Therapy MeetingFindings demonstrate that by degrading neutrophil extracellular traps , DNase I not only facilitates